Aligos Therapeutics, Inc.

Overview

1. "How the company got here" Aligos Therapeutics was founded in 2018. The company is a clinical-stage biopharmaceutical firm focused on creating new treatments for liver and viral diseases. Their mission is to become a leader in treating these conditions, addressing areas with significant unmet medical needs. The company's team has a history of successfully bringing drugs from the initial discovery phase all the way to being available for patients. 2. "What it actually does" Aligos Therapeutics develops medicines that aim to treat liver diseases and viral infections. They focus on creating "best-in-class" therapies, meaning they strive to make drugs that are more effective or safer than existing treatments. Their work involves deep research and development expertise to create a pipeline of potential new medicines. 3. "Chronic Hepatitis B Virus (HBV) Infection" This is a major focus for Aligos Therapeutics, as chronic Hepatitis B is a widespread liver disease that can lead to liver cancer. The company is developing two main drug candidates for this: Pevifoscorvir sodium, an oral small molecule that acts as a capsid assembly modulator (a type of drug that interferes with how the virus replicates), and ALG-170675, an antisense oligonucleotide (ASO) which is a type of therapy that targets the virus's genetic material. These treatments are designed to offer new options for the millions of people worldwide living with this chronic infection. 4. "Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Obesity" Aligos Therapeutics is also developing treatments for MASH, a liver condition characterized by inflammation and fat buildup, and obesity. Their drug candidate for this area is ALG-055009, a small molecule that acts as a THR-ß agonist. This type of drug is intended to help the liver process fats more effectively and reduce inflammation. This segment addresses a growing health concern with a large patient population globally. 5. "Coronavirus Infections" The company has also been involved in developing therapies for coronavirus infections. One of their drug candidates, ALG-097558, is a small molecule designed to inhibit a key enzyme (protease) that the virus needs to replicate. While this program has completed early-stage clinical trials, the company's primary focus appears to be on liver diseases. 6. "What management is betting on now" Aligos Therapeutics is strategically focused on advancing its pipeline of drug candidates for liver and viral diseases, particularly chronic Hepatitis B virus (HBV) infection and MASH. They are prioritizing the development of "best-in-class" therapies, aiming to create treatments that offer significant improvements over existing options. Key priorities include progressing their lead candidates through clinical trials, such as the B-SUPREME study for pevifoscorvir sodium, and exploring strategic partnerships to expand their reach, like the agreement for Greater China rights. The company is also focused on strengthening its financial position to support these development efforts.